NAD+

The safety evidence for NAD+ supplementation is extremely limited based on the provided research. Most evidence focuses on metabolic mechanisms rather than clinical safety data, making it impossible to provide a comprehensive safety assessment.

Available Clinical Trial Safety Data

The evidence includes only a few completed clinical trials:

• One Phase 1/2 trial of nicotinamide riboside (an NAD+ precursor) in systolic heart failure patients (NCT03423342) - no safety outcomes reported in provided data
• One completed trial examining NAD+ supplementation with exercise (NCT04907110) - no safety data provided

Critical Evidence Gaps

No safety data is available from the provided evidence regarding:

• Common or rare side effects
• Serious adverse events
• Drug interactions
• Contraindications
• Dosing-related safety concerns
• Long-term safety profile

Populations of Potential Concern

While specific safety data is lacking, the provided research suggests NAD+ affects fundamental cellular processes including:

• Mitochondrial function
• Metabolic pathways
• Circadian rhythms
• Immune system function

Without adequate safety data, particular caution may be warranted in:

• Pregnant or breastfeeding women
• Children and adolescents
• Patients with metabolic disorders
• Individuals taking medications that affect cellular metabolism

Current Research Status

One Phase 2 trial for atypical Parkinsonism is currently recruiting (NCT06162013), but safety results are not yet available.

Important Disclaimer

The evidence provided contains insufficient safety data to adequately assess the risk profile of NAD+ supplementation. Anyone considering NAD+ supplementation should consult with a healthcare provider, as this analysis cannot provide personalized medical advice or substitute for professional medical evaluation.

The lack of comprehensive safety data in the provided evidence represents a significant limitation in assessing the clinical safety of NAD+ supplementation.